Gemcitabine suppresses malignant ascites of human pancreatic cancer: Correlation with VEGF expression in ascites

Oncology Reports

Volumn 11, Issue 1, 2004, Pages 73-80

  Kuwahara, Kenichi ^a   Sasaki, Tamito ^a   Kobayashi, Kensou ^a   Noma, Bunjirou ^a   Serikawa, Masahiro ^a   Iiboshi, Tomohiro ^a   Miyata, Hideki ^a   Kuwada, Yukio ^a   Murakami, Masateru ^a   Yamasaki, Souichirou ^a   Kariya, Kenji ^a   Morinaka, Kenji ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Gemcitabine; Malignant ascites; Pancreatic ductal carcinoma; VEGF

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CD31 ANTIGEN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; VASCULOTROPIN A;

ANIMAL; ARTICLE; ASCITES; ASCITES FLUID; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL DIVISION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD31; ANTIMETABOLITES, ANTINEOPLASTIC; ASCITES; ASCITIC FLUID; CELL DIVISION; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3543074141     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.1.73     Document Type: Article

References (49)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
2. Brown HR: Kinetics of angiogenesis in small vessels related to mouse parietal peritoneum. Anat Rec 184: 364, 1976.
3. Heuser LS, Taylor SH and Folkman J: Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis. J Surg Res 36: 244-250, 1984. (Pubitemid 14162495)
4. Straube RL: Fluid accumulation during initial stages of tumor growth. Cancer Res 18: 57-65, 1958.
5. Hirabayashi K and Graham J: Genesis of ascites in ovarian cancer. Am J Obstet Gynecol 106: 492-497, 1970.
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
7. Garrison RN, Kaelin LD, Galloway RH and Heuser LS: Malignant ascites. Clinical and experimental observations. Ann Surg 203: 644-651, 1986. (Pubitemid 16062481)
8. Garrison RN, Galloway RH and Heuser LS: Mechanisms of malignant ascites production. J Surg Res 42: 126-132, 1987. (Pubitemid 17024827)
9. Sykes JA: Pharmacologically active substances in malignant ascites fluid. Br J Pharmacol 40: P595, 1970.
10. Greenbaum LM, Grebow P, Johnston M, Prakash A and Semente G: Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation. Cancer Res 35: 706-710, 1975.
11. Maeda H, Matsumura Y and Kato H: Purification and identification of [hydroxyprolyl3] bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 263: 16051-16054, 1988. (Pubitemid 18262016)
12. Matsumura Y, Kimura M, Yamamoto T and Maeda H: Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 79: 1327-1334, 1988. (Pubitemid 20019411)
13. Matsumura Y, Maruo K, Kimura M, Yamamoto T, Konno T and Maeda H: Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 82: 732-741, 1991.
14. White MJ, Miller FN, Heuser LS and Pietsch CG: Human malignant ascites and histamine-induced protein leakage from the normal microcirculation. Microvasc Res 35: 63-72, 1988. (Pubitemid 18036806)
15. Ettinghausen SE, Puri RK and Rosenberg SA: Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80: 177-188, 1988.
16. Ohmura E, Tsushima T, Kamiya Y, Okada M, Onoda N, Shizume K and Demura H: Epidermal growth factor and transforming growth factor induce ascitic fluid in mice. Cancer Res 50: 4915-4917, 1990. (Pubitemid 20257909)
17. Nagy JA, Meyers MS, Masse EM, Herzberg KT and Dvorak HF: Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55: 376-385, 1995.
18. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR and Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993. (Pubitemid 23304407)
19. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF and Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255-1262, 1993. (Pubitemid 24057094)
20. Ferrara N, Houck KA, Jackeman LB, Winer J and Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47: 211-218, 1991.
21. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
22. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB and Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6: 373-378, 1999. (Pubitemid 29260800)
23. Gudjonsson B: Cancer of the pancreas. Fifty years of surgery. Cancer 60: 2284-2303, 1987.
24. Warshaw Al and Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
25. Wanebo HJ and Vezeridis MP: Pancreatic carcinoma in perspective. A continuing challenge. Cancer 78: 580-591, 1996. (Pubitemid 26251517)
26. Yamamoto M: A general view of pancreatic cancer in Japan and a proposal for a more practical staging system. Int J Clin Oncol 4: 267-272, 1999.
27. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4122, 1990.
28. Senger DR, van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324, 1993. (Pubitemid 23293287)
29. Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998. (Pubitemid 28465848)
30. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB Jr and Ellis LM: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5: 3364-3368, 1999.
31. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D and Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85: 178-187, 1999. (Pubitemid 29031373)
32. Shibuya M, Luo JC, Toyoda M and Yamaguchi S: Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol 43: S72-S77, 1999. (Pubitemid 29244637)
33. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S and Parham GP: Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 20: 177-181, 1999. (Pubitemid 29286483)
34. Sherer DM, Eliakim R and Abulafia O: The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 50: 217-224, 2000.
35. Luo JC, Toyoda M and Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58: 2594-2600, 1998. (Pubitemid 28275431)
36. Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994. (Pubitemid 24324908)
37. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
38. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ and Radinsky R: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6: 1936-1948, 2000. (Pubitemid 30305093)
39. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R and Fidler IJ: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935, 2000. (Pubitemid 30395817)
40. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J and Fidler IJ: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16: 359-370, 2001. (Pubitemid 33151113)
41. Baker CH, Solorzano CC and Fidler IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62: 1996-2003, 2002. (Pubitemid 34408443)
42. Appelqvist P, Silvo J, Salmela L and Kostiainen S: On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol 20: 238-242, 1982. (Pubitemid 12048430)
43. Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwartz PE, Lorber MI, Handschumacher RE and Pizzorno G: Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol 15: 1945-1952, 1997. (Pubitemid 27209525)
44. Lind SE, Cashavelly B and Fuller AF: Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary. Surg Gynecol Obstet 166: 519-522, 1988.
45. Plaxe SC, Christen RD, O'Quigley J, Braly PS, Freddo JL, McClay E, Heath D and Howell SB: Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs 16: 147-153, 1998. (Pubitemid 28495216)
46. Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C and Fullem L: Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 8: 2054-2061, 1990.
47. Muggia FM, Jeffers S, Muderspach L, Roman L, Rosales R, Groshen S, Safra T and Morrow CP: Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Gynecol Oncol 66: 290-294, 1997. (Pubitemid 27335419)
48. Smith EM and Jayson GC: The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15: 59-72, 2003. (Pubitemid 36348121)
49. Markman M: Intraperitoneal chemotherapy as treatment of ovarian carcinoma: why, how and when? Obstet Gynecol Surv 42: 533-539, 1987.